HARCP

HEROIN ADDICTION AND
RELATED CLINICAL PROBLEMS

The official journal of
EUROPAD - European Opiate Addiction Treatment Association
WFTOD - World Federation for the Treatment of Opioid Dependence
Editor: Icro Maremmani, MD - Pisa, Italy, EU
Associate Editors:
Thomas Clausen, MD - Oslo, Norway
Pier Paolo Pani, MD - Cagliari, Italy, EU
Marta Torrens, MD - Barcelona, Spain, EU
Statistical Editor:
Mario Miccoli, PhD - Pisa, Italy, EU

HARCP Archives

Browse by article Browse by volume    

Heroin Addiction and Related Clinical Problems: 2020, 22, N6 (pages: 39 - 48)

Is the Non-Medical Use of Pregabalin Related to Reward/Relief Craving Coupled to an Unbalanced Opioid System?

Della Rocca F., Cosentino V., Carbone M.G., Maremmani A.G.I., and Maremmani I.

Summary: Background: Pregabalin is an antiepileptic drug belonging to the gabapentinoid family used for antinociceptive, anticonvulsant and anxiolytic purposes. In recent years, a growing body of observational studies and surveys has been highlighting the increasingly common recourse to a non-medical use of pregabalin. Young subjects with a past or current history of substance use disorder, mainly arising from the taking of opiates appear to be at risk of developing the non-medical use of pregabalin. The pathogenetic mechanism underlying this phenomenon is unclear. Case Report: In the present paper, we describe the case of a 25-year-old male who was hospitalized in the 2nd Psychiatric Unit of Psychiatry at the University of Pisa for a non-medical use of pregabalin. We speculated on the reasons why the patient developed a pregabalin use disorder. Was pregabalin being used to gain a ‘primary' reward or as a ‘booster' to enhance the effects of other substances? Alternatively, was it being self-administered to achieve relief from withdrawal symptoms caused by other substances, or for pain management? Conclusions: This paper adds to the growing body of literature suggesting that pregabalin has a non-medical use potential. When prescribing pregabalin, clinicians should consider completing a risk assessment for non-medical use, especially in patients with a Substance Use Disorder history. Therefore, pregabalin off-label prescriptions should be carefully considered.

 

EUROPAD - European Opiate Addiction Treatment Association
Brussels, Belgium, EU
P. IVA 01681650469 – Codice Fiscale 94002580465 Reserved Area
Tel/Phone: 0584 - 790073 - Email: info@heroinaddictionrelatedclinicalproblems.org
Start of page